Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12616827

Defining disordered personality functioning.

Gordon Parker·Lindsay Both·Amanda Olley·Dusan Hadzi-Pavlovic·Penelope Irvine·George Jacobs
View original source ↗Export metadata ↓

Abstract

Current definitions of the PDs commonly combine descriptors of personality style and disordered personality functioning. This leads to artefactual comorbidity of formally separate disorders and compromising of diagnostic precision. We suggest that measurement of disordered functioning alone might provide a more efficient and precise first-level measure of PD. We review candidate constructs for the definition of disordered functioning and consider how constructs might be refined in subsequent research and lead to applied measures.

Explore related subjects

Behavioral SymptomsHumansPersonality DisordersJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gordon Parker, Lindsay Both, Amanda Olley, Dusan Hadzi-Pavlovic, Penelope Irvine, George Jacobs. 2002. Defining disordered personality functioning.. https://doi.org/10.1521/pedi.16.6.503.22139

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Frontal syndrome and disorders of executive functions.

The study of executive functions began with the early description of behavioural disorders induced by frontal damage. The development of experimental neuropsychology has led to the description of a large variety of cognitive disorders. Such approach has generated numerous tests that are used in clinical practice. More recently, theoretical approaches have proposed an organisation of executive processes and have documented the diversity of executive functions and related anatomy. These studies have deeply influenced the clinical approach, the assessment and the diagnosis of planning and executive disorders. For clinical practice, these data have favoured specific assessment of some key behavioural and cognitive deficits based on a battery of tests.

Behavioral Symptoms↗
PubMed2002

The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.

Multiple behavioural and psychological symptoms of dementia (BPSD) are commonly associated with all dementia subtypes, and worsen during disease progression. BPSD arise due to impairment of cholinergic function in the cortex, hippocampus and related limbic systems. Recent studies have investigated the effect of cholinesterase inhibitors on BPSD. The dual acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitor rivastigmine was shown to have several potential advantages over the AChE-selective inhibitors donepezil and galantamine for the treatment of BPSD. Rivastigmine appears to be effective across the range of dementia severity from mild to severe, and across the spectrum of dementia (Alzheimer's disease [AD], the AD variant with Lewy bodies, Parkinson's disease dementia and vascular dementia subtypes). It also appears to have a disease-modifying potential. Rivastigmine improved a wider range of behavioural symptoms (apathy, anxiety/depression, hallucinations and delusions) than donepezil and galantamine (which improved apathy and depression/anxiety only). Unlike donepezil, rivastigmine reduced the need for psychotropic medications to treat BPSD. Dual inhibition of AChE and BuChE and brain-region selectivity through preferential inhibition of the G1 isoform of AChE may provide the underlying reasons for the apparently greater and broader efficacy of rivastigmine over AChE-selective inhibitors for the treatment of BPSD. However, randomised, controlled trials are required to compare dual inhibitors, such as rivastigmine, and AChE-selective agents, to confirm and quantify any differences in their effects on BPSD.

Behavioral Symptoms↗